Betulinic acid self-assembled nanoparticles for effective treatment of glioblastoma
Authors:
Open Access
- 21 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 20 (1) , 1-13
Abstract
Background: Glioblastoma (GBM) is the most common and fatal primary tumor in the central nervous system (CNS). Due to the existence of blood–brain barrier (BBB), most therapeutics cannot efficiently reach tumors in the brain, and as a result, they are unable to be used for effective GBM treatment. Accumulating evidence shows that delivery of therapeutics in form of nanoparticles (NPs) may allow crossing the BBB for effective GBM treatment.Methods: Betulinic acid NPs (BA NPs) were synthesized by the standard emulsion approach and characterized by electron microscopy and dynamic light scattering analysis. The resulting NPs were characterized for their anti-tumor effects by cell viability assay, EdU-DNA synthesis assay, cell cycle assay, mitochondrial membrane potential, and PI-FITC apoptosis assay. Further mechanistic studies were carried out through Western Blot and immunostaining analyses. Finally, we evaluated BA NPs in vivo for their pharmacokinetics and antitumor effects in intracranial xenograft GBM mouse models.Results: BA NPs were successfully prepared and formed into rod shape. BA NPs could significantly suppress glioma cell proliferation, induce apoptosis, and arrest the cell cycle in the G0/G1 phase in vitro. Furthermore, BA NPs downregulated the Akt/NFκB-p65 signaling pathway in a concentration dependent manner. We found that the observed anti-tumor effect of BA NPs was dependent on the function of CB1/CB2 receptors. Moreover, in the intracranial GBM xenograft mouse models, BA NPs could effectively cross the BBB and greatly prolong the survival time of the mice.Conclusions: We successfully synthesized BA NPs, which could cross the BBB and demonstrated a strong anti-tumor effect. Therefore, BA NPs may potentially be used for effective treatment of GBM.GraphicalKeywords
Funding Information
- National Natural Science Foundation of China (82072764, 82001311)
This publication has 26 references indexed in Scilit:
- Betulinic Acid and its Derivatives as Potential Antitumor AgentsMedicinal Research Reviews, 2015
- Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cellsOncotarget, 2015
- Recent studies on betulinic acid and its biological and pharmacological activityEXCLI Journal, 2015
- Betulinic Acid Decreases Specificity Protein 1 (Sp1) Level via Increasing the Sumoylation of Sp1 to Inhibit Lung Cancer GrowthMolecular Pharmacology, 2012
- Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast CancerMolecular Cancer Therapeutics, 2012
- Betulinic Acid and Its Derivatives: A Review on their Biological PropertiesCurrent Medicinal Chemistry, 2005
- Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cellsCancer Letters, 2002
- Betulinic Acid-Induced Apoptosis in Glioma Cells: A Sequential Requirement for New Protein Synthesis, Formation of Reactive Oxygen Species, and Caspase ProcessingThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosisNature Medicine, 1995
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal of Cancer, 1993